Reneo Pharmaceuticals, Inc. RPHM
We take great care to ensure that the data presented and summarized in this overview for Reneo Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RPHM
Top Purchases
Top Sells
About RPHM
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Insider Transactions at RPHM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2025
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
1,813,439
-100.0%
|
$1,813,439
$1.85 P/Share
|
|
May 15
2025
|
Acorn Bioventures, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,129,730
+50.0%
|
$1,129,730
$1.85 P/Share
|
|
May 15
2025
|
Acorn Bioventures, L.P. |
BUY
Open market or private purchase
|
Direct |
270,270
+13.65%
|
$270,270
$1.85 P/Share
|
|
May 12
2025
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
24,300
-1.32%
|
$24,300
$1.99 P/Share
|
|
Apr 07
2025
|
Jason A. Leverone Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,844
-12.25%
|
$3,688
$2.67 P/Share
|
|
Apr 07
2025
|
Nicholas A Saccomano President and CEO |
SELL
Open market or private sale
|
Direct |
516
-12.29%
|
$1,032
$2.67 P/Share
|
|
Apr 04
2025
|
Jason A. Leverone Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,278
-7.83%
|
$3,834
$3.33 P/Share
|
|
Apr 04
2025
|
Nicholas A Saccomano President and CEO |
SELL
Open market or private sale
|
Direct |
358
-7.86%
|
$1,074
$3.33 P/Share
|
|
Mar 31
2025
|
Edward T Mathers |
BUY
Grant, award, or other acquisition
|
Direct |
2,580
+50.0%
|
-
|
|
Mar 31
2025
|
Isaac Manke |
BUY
Grant, award, or other acquisition
|
Direct |
3,469
+50.0%
|
-
|
|
Oct 07
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Direct |
102,076
+50.0%
|
-
|
|
Oct 07
2024
|
Braden Michael Leonard |
BUY
Other acquisition or disposition
|
Indirect |
345,739
+50.0%
|
-
|
|
Oct 04
2024
|
Nicholas A Saccomano President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,556
+50.0%
|
-
|
|
Oct 04
2024
|
Jason A. Leverone Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,331
+50.0%
|
-
|
|
Oct 04
2024
|
R Michael Carruthers |
BUY
Grant, award, or other acquisition
|
Direct |
4,939
+47.57%
|
-
|
|
Sep 25
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
68,746
+1.95%
|
$68,746
$1.5 P/Share
|
|
Sep 24
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
29,600
+0.87%
|
$29,600
$1.41 P/Share
|
|
Sep 18
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
806
+0.02%
|
$806
$1.4 P/Share
|
|
Sep 17
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
55,300
+1.62%
|
$55,300
$1.36 P/Share
|
|
Sep 16
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
172,747
+4.97%
|
$172,747
$1.37 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 31.9K shares |
|---|---|
| Other acquisition or disposition | 448K shares |
| Open market or private purchase | 2.19M shares |
| Open market or private sale | 1.84M shares |
|---|